CVS Health (NYSE:CVS) Unveils New GLP-1 Strategy Amid Strong Market Performance

Font: Financial Modeling Prep  • Jun 22, 2026

• CVS Health (NYSE:CVS) is demonstrating strong market momentum, with its stock price nearing its 52-week high, reflecting robust performance.
• The company is strategically expanding into the GLP-1 medication market, leveraging its extensive network of 9,000 pharmacies and virtual MinuteClinic services.
• To enhance patient access and affordability, CVS Health is implementing a $50 monthly copay for Medicare patients and offering $49 virtual weight management visits.

CVS Health is a major American healthcare company. It operates thousands of retail pharmacies, provides pharmacy benefit management services, and offers health insurance through its Aetna division. Its main competitors include Walgreens in the retail pharmacy space and other large insurers like Cigna in the health benefits sector.

As highlighted by Zacks Investment Research, CVS is considered a top momentum stock for long-term investment. This momentum is reflected in its recent trading, with the stock price at $102.55, an increase of 4.30% for the day. The price is currently near its 52-week high of $102.77, showing strong recent performance.

In response to growing demand, CVS is launching a new strategy for GLP-1 medications, which are popular for weight management. As highlighted by PR Newswire, this plan covers its 9,000 pharmacies and virtual MinuteClinic services. This move positions the company to capitalize on a significant trend in the U.S. healthcare market.

To improve access, the company is introducing a $50 monthly copay for eligible Medicare patients to lower costs. Its MinuteClinic is also expanding virtual care for weight management. These $49 visits allow clinicians to evaluate patients and prescribe GLP-1 therapy when it is appropriate, making treatment more convenient for many.

The strategy also includes personalized support from pharmacists and related over-the-counter products to help patients manage side effects. With a market capitalization of approximately $130.85 billion, which is the total value of all its shares, CVS is making a significant investment to support patients using these new therapies.